apricus wealth LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

apricus wealth LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,385 shares of the biopharmaceutical company’s stock after selling 14,585 shares during the quarter. Pfizer makes up approximately 1.6% of apricus wealth LLC’s holdings, making the stock its 27th largest holding. apricus wealth LLC’s holdings in Pfizer were worth $2,398,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Gradient Investments LLC boosted its holdings in Pfizer by 19.8% in the fourth quarter. Gradient Investments LLC now owns 1,109,832 shares of the biopharmaceutical company’s stock worth $29,444,000 after purchasing an additional 183,403 shares during the period. Curated Wealth Partners LLC lifted its position in shares of Pfizer by 25.6% in the 4th quarter. Curated Wealth Partners LLC now owns 45,337 shares of the biopharmaceutical company’s stock worth $1,203,000 after buying an additional 9,236 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Pfizer by 10.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company’s stock valued at $2,023,000 after buying an additional 7,072 shares during the period. CX Institutional raised its stake in Pfizer by 9.1% during the fourth quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock worth $1,337,000 after acquiring an additional 4,183 shares during the period. Finally, Sound Income Strategies LLC lifted its holdings in Pfizer by 10.0% in the fourth quarter. Sound Income Strategies LLC now owns 764,822 shares of the biopharmaceutical company’s stock worth $20,291,000 after acquiring an additional 69,416 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Guggenheim dropped their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Down 1.3 %

NYSE PFE opened at $26.10 on Friday. The company has a market capitalization of $147.89 billion, a P/E ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $26.08 and its 200 day simple moving average is $27.95.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.17) EPS. Equities research analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.59%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.